Cloning

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Shimon Slavin

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

National STEM Scholars Announced for 2021

Retrieved on: 
Thursday, July 22, 2021
Articles, Branches of biology, Biology, Induced stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Stem, Science, technology, engineering, and mathematics, Western Kentucky University

STEM Scholars convene on WKU's campus for a week of advanced STEM training and finalize their projects with input from their STEM Scholar class colleagues.

Key Points: 
  • STEM Scholars convene on WKU's campus for a week of advanced STEM training and finalize their projects with input from their STEM Scholar class colleagues.
  • The 2021 National STEM Scholar class was hosted by The Gatton Academy May 30th to June 5th on the campus of WKU in Bowling Green, KY.
  • By June 2021, STEM Scholars will have directly and indirectly impacted an estimated 66,000 middle school students in the U.S.
  • The National Stem Cell Foundation is a 501(c)3 non-profit organization that funds adult stem cell and regenerative medicine research, connects children with limited resources to clinical trials for rare diseases and underwrites the National STEM Scholar Program for middle school science teachers inspiring the next generation of STEM pioneers nationwide.

Global Gene Expression Analysis Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Health, General Health, Molecular biology, Cloning, Gene

The "Gene Expression Analysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Expression Analysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global gene expression analysis market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the global gene expression analysis market to grow at a CAGR of around 10% during 2021-2026.
  • Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2021 Financial Results

Retrieved on: 
Friday, July 16, 2021
Branches of biology, Biology, Stem cells, Life sciences, Blood, Cryo-Cell International, Childbirth, Cord blood bank, Cloning, Cord blood, Draft:Americord Registry, Cryo-Save

OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.

Key Points: 
  • OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.
  • Consolidated revenues for the second quarter of fiscal 2021 were $7.21 million compared to $7.87 million for the second quarter of fiscal 2020, an 8% decrease.
  • The revenues for the second quarter of fiscal 2021 consisted of $7.16 million in processing and storage fee revenue and $46,000 in public banking revenue compared to $7.40 million in processing and storage fee revenue, $57,000 in product revenue, $214,000 in public banking revenue and $202,000 in license and royalty income for the second quarter of fiscal 2020.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Worldwide Stem Cell Banking Industry to 2026 - Featuring CBR Systems, Cordlife and Lifecell Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Stem cells, Articles, Branches of biology, Biology, Stem cells, Biotechnology, Cell biology, Cloning, Stem-cell therapy, Bank, Science, technology, engineering, and mathematics

The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global stem cell banking market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the global stem cell banking market to reach a value of US$ 21.5 Billion by 2026.
  • Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy.

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Biology, Articles, Biotechnology, Pharmaceutical industry, Cloning, Induced stem cells, Developmental biology, Stem cell, Good manufacturing practice, Biopharmaceutical

LOS ANGELES, July 15, 2021 /PRNewswire/ -- Generate Life Sciences (Generate) today announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, Calif. which will enable end-to-end manufacturing for newborn stem cell biologics.

Key Points: 
  • LOS ANGELES, July 15, 2021 /PRNewswire/ -- Generate Life Sciences (Generate) today announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, Calif. which will enable end-to-end manufacturing for newborn stem cell biologics.
  • This facility will represent a big step in the evolution of Generate and its broader life sciences platform adding the role of a personalized therapeutics developer with in-house manufacturing capabilities to its core international donor gamete, genetics service and newborn stem cell preservation business.
  • The new Generate facility has been designed to harness these inherent properties to maximize bioprocessing efficiency and manufacture at scale.
  • "The La Jolla GMP facility will be a crucial addition to Generate's vision for our newborn stem cell operation," said Jaime Shamonki, MD, Generate's Chief Medical Officer.

Turnstone Biologics Appoints Stewart Abbot, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, June 29, 2021
Biotechnology, Science, Health, Other Science, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Immunotherapy

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the appointment of Stewart Abbot, Ph.D., as the Companys Chief Scientific Officer.

Key Points: 
  • Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the appointment of Stewart Abbot, Ph.D., as the Companys Chief Scientific Officer.
  • Dr. Abbot joins Turnstone from Adicet Bio where he was Chief Scientific and Chief Operating Officer, leading R&D activities for allogeneic gamma delta T-cell therapies.
  • Prior to this, he served as Chief Development Officer at Fate Therapeutics and oversaw development of hematopoietic and induced pluripotent stem cell-based immunotherapeutics.
  • in Biomedical Engineering from the University of Strathclyde in Glasgow, and Ph.D. in Pathology from the University of London.

Meso Numismatics and Global Stem Cell Group Enter Final Definitive Agreement

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

LAS VEGAS, NV, June 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, is pleased to announce that the Final Definitive Agreement with Global Stem Cells Group (GSCG) has been signed.

Key Points: 
  • LAS VEGAS, NV, June 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, is pleased to announce that the Final Definitive Agreement with Global Stem Cells Group (GSCG) has been signed.
  • We are very pleased to have entered into the definitive agreement with Global Stem Cells, said Dave Christensen, CEO of Meso.
  • For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
    About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean.
  • Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor

Retrieved on: 
Wednesday, June 23, 2021
Research, Infectious diseases, Genetics, Clinical trials, Stem cells, Biotechnology, Health, Science, Oncology, Branches of biology, Biology, Life sciences, Biotechnology, Induced stem cells, Stem cells, Cloning, Cell biology, Induced pluripotent stem cell

The regenerative medicine research was presented at the 2021 International Society for Stem Cell Research virtual annual meeting.

Key Points: 
  • The regenerative medicine research was presented at the 2021 International Society for Stem Cell Research virtual annual meeting.
  • We are excited by these preclinical proof-of-concept data demonstrating that we can rapidly generate neurons with mature markers using optimized, transient mRNA transcription factor expression.
  • Cell Squeeze technology can generate reprogrammed cells by controlling the magnitude and timing of single or multiple cell programming factors.
  • Together these data show the potential of the Cell Squeeze technology to rapidly reprogram cells for regenerative medicine applications.

FDA Authorizes Simultaneous Stem Cell Trials for Parkinson’s

Retrieved on: 
Monday, June 21, 2021
Research, FDA, Clinical trials, Philanthropy, Stem cells, Other Health, Biotechnology, Health, Foundation, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Induced stem cells, Cloning, Mesenchymal stem cell, Stem-cell therapy, Cell therapy

This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.

Key Points: 
  • This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.
  • HBSCRF will become the first research organization in the U.S. to conduct simultaneous trials examining effects of administering the patients own cells (autologous) and donor cells (allogeneic) on the same disease condition.
  • We have to explore every facet of how adipose-derived mesenchymal stem cells act in this disease condition, says HBSCRF Founder Donna Chang.
  • Our primary research focus has always been on autologous stem cells, but in COVID, for example, when we ran three simultaneous studies in prevention and treatment, we encountered a situation where people needed cells but did not have their stem cells banked.